Overview
IMTX market data
Price History
IMTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.61 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.35 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -574.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.05 – $12.41 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.3B · P/B 2.52 · P/S 29.89.
Company News
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual MeetingGlobenewswire Inc · Jun 1, 2026, 12:15 PM
Immatics Announces Extended Data From Phaseb Clinicla Trial Evaluating Anzu-Cel PRAME TCR T-Cell Therapy In Heavily Pretreated Patients With Advanced Melanoma At ASCO Annual MeetingBenzinga · Jun 1, 2026, 12:02 PM
Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightGlobenewswire Inc · May 28, 2026, 5:15 PM